So now the big question is, how realistic is that level of transparency in todays healthcare market
Disclosures: Brett McGettigan: Nothing to Disclose, Dawood Al Dawood: Nothing to Disclose, Harmeet Malhi: MERCK: Consultant, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor 1569 HEPATIC METHYLTRANSFERASE PROTEINS MEDIATE PNPLA3-I148M-DRIVEN LIPID DROPLET DYNAMICS IN FATTY LIVER Xinshou Ouyang 1 Yan Zhang 2 Suyavaran ARUMUGAM 2 Shi-Ying Cai 1 Wanqing Liu 3 Wajahat Mehal 1 , 1 Yale University, 2 Yale School of Medicine, 3 Wayne State University Background: The accumulation of Lipid droplets (LDs) characterizes fatty liver in metabolic dysfunction-associated fatty liver disease (MAFLD) and alcohol-associated liver disease (ALD), closely tied to genetic variants, particularly PNPLA3 -I148M
Social Workers As a Jointly Accredited Organization, ASAM is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program
PlexusDx Precision Peptide Genetic Test identifies these predispositions and should be interpreted with a qualified healthcare provider to support more personalized medication discussions
